Annual Epidemiological Report 2009 [2007 data]
This edition of the Annual Report gives special attention to vaccine-preventable diseases and immunisation programmesin the European Union (EU) and European Economic Area (EEA) countries. This edition was revised January and June 2010 and has authority over the print edition.
- Antimicrobial resistance
- Avian influenza virus
- Emerging disease
- Food- and waterborne diseases
- Healthcare-associated infections
- HIV infection
- Influenza in humans, avian origin
- Influenza in humans, seasonal
- Sexually transmitted infections
- Vaccine preventable diseases
- Vector-borne disease
Healthcare-associated infections: Clostridium difficile infections - Annual Epidemiological Report for 2016
In 2016, 20 EU/EEA countries reported CDI data to ECDC for 593 surveillance periods from 556 hospitals.
Rapid risk assessment: Carbapenem-resistant Acinetobacter baumannii in healthcare settings – 8 December 2016
This risk assessment provides an overview of the epidemiological situation in Europe and describes a number of response options.
Rapid risk assessment: Regional outbreak of New Delhi metallo-betalactamase-producing carbapenem-resistant Enterobacteriaceae, Italy, 2018–2019
A large outbreak of New Delhi metallo-beta-lactamase (NDM)-producing carbapenem-resistant Enterobacteriaceae (CRE) has been reported from the Tuscany region in Italy. Between November 2018 and May 2019, seven Tuscan hospitals notified a total of 350 cases.
Rapid risk assessment: Carbapenemase-producing (OXA-48) Klebsiella pneumoniae ST392 in travellers previously hospitalised in Gran Canaria, Spain
This rapid risk assessment evaluates the risk of transmission and further spread of OXA-48-producing Klebsiella pneumonia e ST392 from travellers having sought medical care in Gran Canaria to healthcare facilities in their country of origin in the EU/EEA.
Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae - first update
This update of the 2016 ECDC Rapid Risk Assessment on carbapenem-resistant Enterobacteriaceae (CRE) evaluates the risk for patients and healthcare systems in EU/EEA countries due to the global spread of CRE.
Annual Epidemiological Report on Communicable Diseases in Europe 2007 [2005 data]
Annual Epidemiological Report on Communicable Diseases in Europe 2007
Annual Epidemiological Report on communicable diseases in Europe 2007 - Executive Summary [2005 data]
Annual Epidemiological Report on communicable diseases in Europe 2007 - Executive Summary
Communicable Disease Threats Report, 3-9 June 2018, week 23
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 3-9 June 2018 and includes updates on dengue, Vibrio growth in the Baltic Sea, measles, rubella, hepatitis A, mass gathering monitoring, Carbapenem-resistant Enterobacteriaceae, Ebola virus disease, West Nile virus, polio and MERS-CoV.
- Carbapenem-resistant Enterobactericae
- Democratic Republic of the Congo
- Ebola haemorrhagic fever
- Ebola outbreak - North Kivu, Ituri, DRC
- Hepatitis A
- La Réunion
- Middle East respiratory syndrome coronavirus
- Public health threat
- West Nile virus infection
Carbapenem resistant Enterobacteriaceae - second update
Carbapenem resistance in Enterobacteriaceae such as Klebsiella pneumoniae and Escherichia coli poses a significant threat to patients and healthcare systems in all European Union/European Economic Area (EU/EEA) countries. Carbapenem-resistant Enterobacteriaceae (CRE) infections are associated with high mortality, primarily due to delays in administration of effective treatment and the limited availability of treatment options. Hypervirulent carbapenem-resistant K. pneumoniae strains have been reported presenting an additional threat with a potential for global dissemination. The spread of high risk clones and plasmids carrying carbapenemases in healthcare settings is a major cause of the spread of CRE in EU/EEA countries. Recent events of cross-border importation after patient transfer and large regional outbreaks as well as the worsening epidemiologic situation of carbapenemase-producing CRE in the EU/EEA highlight the high risk for further spread of CRE and the need for enhanced control efforts. Options for control are outlined in the respective section below.